CELL INTELLIGENCE · 肿瘤细胞治疗研究

Selinexor 增强 NK 细胞对多发性骨髓瘤的活化

Selinexor potentiates NK cell activation against multiple myeloma.

这些数据揭示，selinexor 选择性破坏 MM 中的 2A:HLA-E 免疫检查点轴，并增强 NK 细胞活化以及对 MM 细胞的 ADCC。

免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

嵌合抗原受体-T 治疗后发生的 T 细胞淋巴瘤：一个值得关注的问题？

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

血液系统恶性肿瘤中的 CD74：从 MHC 分子伴侣到治疗靶点

CD74 in hematological malignancies: from MHC chaperone to therapeutic target.

CAR-T 细胞治疗相关凝血病：从免疫血栓风暴机制到精准管理策略

CAR-T cell therapy-associated coagulopathy: From immunothrombotic storm mechanisms to precision management strategies.

我如何预防接受双特异性抗体治疗的晚期 B 细胞恶性肿瘤成人患者的感染

How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.

CAR-T 细胞免疫治疗后 T 细胞淋巴瘤的综合综述

A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy.

多发性骨髓瘤中 T 细胞重定向治疗的皮肤毒性：EADV 工作组立场文件与实践建议

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.